Actively Recruiting
Antibiotic Dosing in Pediatric Intensive Care
Led by University Hospital, Ghent · Updated on 2026-01-16
640
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University Hospital, Ghent
Lead Sponsor
U
University Hospital, Antwerp
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research focuses on understanding how antibiotics behave in the bodies of critically ill newborns, infants, and children aged from 1.8 kilograms up to 15 years who are admitted to pediatric intensive care. The study aims to evaluate if current dosing regimens achieve effective blood concentrations of antibiotics such as amoxicillin-clavulanate, piperacillin-tazobactam, vancomycin, teicoplanin, meropenem, ciprofloxacin, and amikacin. This information is important for guiding safe and effective antibiotic use in young patients under intensive care. Participants receive routine clinical care including treatment with one of the listed antibiotics administered through intermittent or continuous infusion. Blood, and in some cases urine, samples are collected from existing arterial or intravenous lines to monitor antibiotic levels. These procedures are performed during usual care without additional experimental treatments. During the study, patients will have their first-dose and steady-state blood concentrations of antibiotics measured and compared with targets for maximum antimicrobial activity. The study also collects urine samples for some antibiotics. Researchers aim to understand how well current antibiotic doses reach desired levels to guide future dosing strategies. Participation involves blood and urine sampling while receiving standard care, with safety monitored throughout the study period, which is expected to last approximately two years.
CONDITIONS
Brief Title
Antibiotic Dosing in Pediatric Intensive Care
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted to the pediatric intensive care unit
- Patient age/weight between 1.8 kilograms and 15 years
- Patient receiving antibiotic treatment with piperacillin-tazobactam, amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, or amikacin via intermittent or continuous infusion according to institutional guidelines
- Intra-arterial or intravenous access other than the drug infusion line available for blood sampling; arterial line preferred
You will not qualify if you...
- No catheter in place for blood sampling
- Absence of parental or patient consent
- Known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones, or aminoglycosides
- Use of extracorporeal circuits such as haemodialysis, ECMO, or peritoneal dialysis
Research Team
P
Pieter De Cock, PharmD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here